Unverified
Food noise dropped
Evening food noise dropped, which was the whole point. Nothing else to add.
Metabolic Research
Retatrutide (LY-3437943)
Triple Receptor Agonist
30 mg / Lyophilized powder
Pricing pendingPrice for this size is coming soon. Ordering will open once pricing is confirmed.
Brand vial shown. Refer to the product details for compound and quantity.
Retatrutide is a novel triple-agonist peptide developed by Eli Lilly that simultaneously targets GLP-1, GIP, and glucagon receptors. It represents the most advanced multi-receptor approach to metabolic research, with Phase 2 clinical trial data published in the New England Journal of Medicine showing unprecedented results in weight management studies.
Molecular Formula
C189H300N52O59
Molecular Weight
4113.7 g/mol
Example report / Inventory batch pending
Lumira / Retatrutide / 5mg sample
99.8%
Reported sample purity · HPLC
See the science.
Read the report.
Third-party analysis by Pacific Coast Biologics.
Report issued July 21, 2026.
Research Areas
- Metabolic syndrome
- GLP-1/GIP/glucagon receptor signaling
- Energy expenditure pathways
- Lipid metabolism
- Hepatic fat reduction
Mechanism of Action
Retatrutide activates three receptors simultaneously: GLP-1 (slows gastric emptying, promotes satiety signaling), GIP (enhances insulin sensitivity, affects fat tissue metabolism), and glucagon (increases energy expenditure, promotes hepatic lipid oxidation). This triple mechanism differentiates it from single-agonists (semaglutide) and dual-agonists (tirzepatide).
Storage & Handling
Storage
Store lyophilized powder at -20°C. Once reconstituted, store at 2-8°C and use within 21 days.
Reconstitution
Reconstitute with bacteriostatic water. Add solvent slowly along the vial wall. Do not shake — gently swirl until fully dissolved.
From the community
Customer reviews.
Feedback on Retatrutide.
Customer accounts are anecdotal and do not establish safety or efficacy. Products are for laboratory research use only.
- Unverified
Clothes before scale
Low expectations. I stopped finishing plates out of habit. Fine by me.
- Unverified
Hard to tell
Could be the extra sleep. Not convinced. The default snack run just stopped happening.
- Unverified
Early nausea, then fine
Appetite fell enough that I had to schedule protein. That's the review.
- Unverified
Evenings got quiet
Skeptical of anything that gets talked about this much. Gave it a clean 4 weeks without stacking three other new things. Week one nausea if I ate fast, then it settled — that's the part I'd repeat. Could still be coincidence. I'm writing down what I noticed, not a mechanism. Dose I started on was enough. I didn't chase a higher one. Not dramatic. Useful.
- Unverified
Had to remember protein
The trend was down without a crash-diet feeling. Nothing else to add.
A closer reading
The scientific review.
One selected primary paper, with its findings and limits. A starting point for reading, not a complete assessment of the evidence.
Triple-receptor signaling in an obesity trial
Phase 2 randomized trial · 338 adults
What the researchers observed
A placebo-controlled trial reported greater weight reduction with retatrutide over 48 weeks in adults meeting defined BMI and health criteria. Safety was also assessed.
What this does not establish
This selected 2023 trial concerns a controlled investigational formulation and population. It does not validate a retail research vial or establish its safety.
Jastreboff AM et al. · New England Journal of Medicine · 2023
Read the primary paper PMID 37366315Research Use Only: This product is sold for laboratory and research purposes only. It is not intended for human consumption and is not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you agree to use this product solely for legitimate research purposes.